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Abstract
Purpose Traditionally, total thyroidectomy has been advocat-
ed for patients with tumors larger than 1 cm. However, ac-
cording to the ATA and NCCN guidelines (2015, USA), pa-
tients with tumors up to 4 cm are now eligible for lobectomy.
A rationale for adhering to total thyroidectomy might be the
presence of contralateral carcinomas. The purpose of this
study was to describe the characteristics of contralateral carci-
nomas in patients with differentiated thyroid cancer (DTC)
larger than 1 cm.
Methods A retrospective study was performed including pa-
tients from 17 centers in 5 countries. Adults diagnosed with
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DTC stage T1b-T3 N0-1a M0 who all underwent a total thy-
roidectomy were included. The primary endpoint was the
presence of a contralateral carcinoma.
Results A total of 1313 patients were included, of whom 426
(32 %) had a contralateral carcinoma. The contralateral carci-
nomas consisted of 288 (67 %) papillary thyroid carcinomas
(PTC), 124 (30 %) follicular variant of a papillary thyroid
carcinoma (FvPTC), 5 (1 %) follicular thyroid carcinomas
(FTC), and 3 (1 %) Hürthle cell carcinomas (HTC).
Ipsilateral multifocality was strongly associated with the pres-
ence of contralateral carcinomas (OR 2.62). Of all contralat-
eral carcinomas, 82 % were ≤10 mm and of those 99 % were
PTC or FvPTC. Even if the primary tumor was a FTC or HTC,
the contralateral carcinoma was (Fv)PTC in 92 % of cases.
Conclusions This international multicenter study performed
on patients with DTC larger than 1 cm shows that contralateral
carcinomas occur in one third of patients and, independently
of primary tumor subtype, predominantly consist of
microPTC.
Keywords Differentiated thyroid carcinoma . Contralateral
carcinoma . Papillarymicrocarcinoma . Surgical strategy
Introduction
Differentiated thyroid cancer (DTC) is the most common en-
docrine malignancy and its incidence is rising. The prognosis
is excellent with 10-year survival rates over 90 % irrespective
of the stage of disease [1]. Until recently, in western countries,
treatment of DTC was similar for all stages of macroDTC
(DTC larger than 1 cm): total thyroidectomy followed by ra-
dioactive iodine ablation (RAI) therapy [2, 3]. However, in the
last decade, single-center studies performed in large-volume
centers showed no significant differences in recurrence and
survival rates in patients diagnosed with macroDTC, who
were either treated with lobectomy or total thyroidectomy
[4–7]. This has evoked a new discussion about the optimal
extent of surgery, whereby according to the ATA and NCCN
guidelines (2015, USA), patients with tumors up to 4 cm are
now eligible for lobectomy [8, 9].
Traditional arguments for adhering to total thyroidectomy
are the presence of contralateral carcinomas, the ability to
perform RAI and the use of thyroglobulin as a follow-up
marker. There is, however, increasing support for more selec-
tive use of RAI [9–11]. Contralateral carcinomas are reported
in up to 44 % of patients with DTC [12]. Supporters of total
thyroidectomy argue that contralateral carcinomas could af-
fect disease recurrence and survival [12–15]. Interestingly,
these data are mainly based on patients with microDTC
(DTC smaller than 1 cm) and data on the incidence of contra-
lateral carcinomas in macroDTC is currently scarce [16–21].
We, therefore, aimed to describe the incidence and the
characteristics of contralateral carcinomas, and subsequently
assess determinants correlating with the presence of contralat-
eral carcinomas in patients with macroDTC.
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Patients and methods
Patients
We conducted a descriptive, retrospective, cross-sectional,
multicenter study in a total of 17 centers in 5 countries.
Patients who underwent a total thyroidectomy for DTC, either
in one or two stages, who were operated between January
2000 and December 2012 and aged ≥18 years were included.
Indication for a completion thyroidectomy was confirmation
of DTC larger than 1 cm in the histologic examination of the
lobectomy specimen.
We specifically selected the patients for whom the discus-
sion about the extent of surgery is most relevant. The TNM
stages that were included for the different histological sub-
types were based on the currently recruiting study of Mallick
et al. [10]. This study investigates whether in a subgroup of
low-risk patients ablation can be omitted, without compromis-
ing recurrence or survival rates. This concerns patients with a
papillary thyroid carcinoma (PTC) including, follicular vari-
ant of papillary thyroid carcinoma (FvPTC) with stage pT1b-
T2-T3, N0-N1a-Nx and patients with a follicular thyroid car-
cinoma (FTC) or a Hürthle cell carcinoma (HTC) stages
pT1b-T2, N0-N1a-Nx. The TNM classification from the 7th
edition of the AJCC cancer staging manual was used [22].
In Dutch University Medical Centers, all consecutive pa-
tients whowere operated between 2000 and 2012were includ-
ed since these were only limited numbers. In the high-volume
international centers, 150 patients were randomly generated
from a list that included all patients that fulfilled inclusion
criteria who were operated between 2000 and 2012. Cases
were selected by creating a list of numbers generated by ran-
domization software. Pathologic staging was performed ac-
cording to the AJCC cancer staging manual. In the seven
participating Dutch University Medical Centers, data entry
was performed by the same researcher (WPK). Outside
The Netherlands, data were collected by a local investigator,
using a well-defined data entry manual to ensure homoge-
neous input. The study was approved by the institutional
review board of the University Medical Center Utrecht
(The Netherlands) and in other centers if required.
Characteristics of contralateral carcinomas
The following characteristics of the contralateral carcinomas
were collected: size, histological subtype, and contralateral
multifocality.
Determinants associated with contralateral disease
After performing a pilot study in 30 patients from the UMC
Utrecht and by reviewing the recent literature, 13 determinants
were selected [17, 20, 23–25]. Determinants included sex, age
at diagnosis, size on ultrasound of primary tumor, Bethesda
classification of the primary tumor, postoperative N-stage, size
of the contralateral lobe on pathology (PA), size of the primary
tumor, histological subtype of the primary tumor, multifocality
in the lobe of the primary tumor (ipsilateral multifocality),
angioinvasion, capsular invasion (cells invading the capsule
of the tumor), extrathyroidal growth, and surgical resection
margins of the primary tumor (defined by evaluating resection
margins at pathology). Data were collected from chart re-
views, cytology reports of fine-needle aspiration (FNA), re-
ports of preoperative ultrasound, and the histology reports.
Statistical analysis
All continuous variables were tested for linear association
with the outcome, and in the case of non-linearity, the variable
was categorized in clinically relevant groups [26]. The possi-
ble determinants were assessed for patients with and without
contralateral carcinoma, and univariate regression analysis
and multivariate regression analysis were performed.
Variables with a p value <0.1 in the univariate regression
analysis were selected for multivariate analysis. A p value
<0.05 was considered statistically significant. All statistical
analyses were performed using SPSS version 22 (SPSS Inc.,
Chicago, IL).
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Results
Patients
In total, we included 1313 patients in 17 centers (Table 1). The
mean age at time of surgery was 47.4 years (SD 14.5), and 967
(74 %) patients were female. Total thyroidectomy as primary
surgical intervention was performed in 961 (73 %) patients,
whereas 352 (27 %) patients initially had a lobectomy follow-
ed by completion thyroidectomy. Central lymph node dissec-
tion was not standard of care but was performed dependent of
the presence of suspicious lymph nodes on preoperative ultra-
sound, preference of the surgeon and the clinic. The histolog-
ical subtype of the primary tumor was PTC in 794 patients
(61 %), FvPTC in 354 (27 %), FTC in 116 (9 %), and HTC in
38 (3 %). Unilateral tumor multifocality was seen in 277
(21 %) patients, and 269 (22 %) had central lymph node me-
tastases. Capsular invasion, angioinvasion, and extra-
thyroidal growth were found in 415 (41 %), 247 (22 %), and
231 (19 %) cases, respectively.
Characteristics of contralateral carcinomas
The overall rate of contralateral carcinomas was 32 %
(Table 2). The majority of contralateral carcinomas were
PTC (N=284; 69 %) or FvPTC (N=123; 30 %), while only
a few were FTC (N=4; 1 %) and HTC (N=3; 1 %) (Table 3).
The median size of the contralateral carcinomas was 4 mm
(IQR 2–9 mm). If the primary tumor was non-(Fv)PTC, so
FTC or HTC, the contralateral carcinoma was (Fv)PTC in
92%of the cases. Sixty percent of the contralateral tumors were
5 mm or smaller, 21 % were between 6 and 10 mm, and 18 %
were larger than 10 mm. Of the 82% of tumors sized 10 mm or
smaller, 99 % were PTC or FvPTC. Six out of the total of eight
contralateral FTCs or HTCs were 10 mm or larger (Table 4).
Ipsilateral multifocality was most frequent when the prima-
ry tumor was PTC (23 %), followed by FvPTC (20 %), HTC
(18 %), and FTC (9 %). The histological subtype of the ipsi-
lateral tumors was PTC or FvPTC in 99% of patients (data not
shown).
Determinants associated with contralateral disease
Based on the presence of contralateral carcinomas, univariate
analysis of possible determinants was performed (Table 2).
Contralateral carcinoma was significantly more frequent in
patients with N1a nodal metastasis (OR 1.56 95 % CI 1.18–
2.07), in tumors with extra-thyroidal growth (OR 1.56 95 %
CI 1.16–2.10), and when ipsilateral multifocality was found
(OR 2.64 95% CI 2.01–3.47). When the histologic subtype of
the primary tumor was a FTC or a HTC, the likelihood that a
contralateral carcinoma was present decreased significantly
(FTC: OR 0.38 95 % CI 0.23–0.63; HTC: OR 0.34 95 % CI
0.14–0.83). In multivariate analysis, ipsilateral multifocality
(OR 2.62 95 % CI 1.60–4.29) and lymph node metastasis
(OR 1.89 95 % CI 1.07–3.34) were strongly correlated with
the occurrence of contralateral carcinoma(s). Furthermore,
when the primary carcinomas were FvPTC, FTC, or HTC,
there was a reversed correlation with the occurrence of con-
tralateral carcinomas (FvPTC: OR 0.58 95 % CI 0.35–0.97;
FTC: OR 0.54 95 % CI 0.22–1.33; HTC: OR 0.16 95 % CI
0.03–0.77). The other investigated determinants, sex, age, size
primary tumor (US or PA), angioinvasion, capsular invasion,
negative resection margins, and size of the contralateral lobe,
did not correlate with the presence of contralateral
carcinomas.
Discussion
In this international multicenter study, the incidence and char-
acteristics of contralateral carcinomas were investigated in a
large cohort of patients with primary macroDTC. The rate of
contralateral malignancies was 32 %, and the dominant histo-
logical subtype of the contralateral carcinomas was PTC or
FvPTC (94 %). Median size was 4 mm and 82 % of carcino-
mas was <1 cm. No correlation between histological subtype
of the primary tumor and the subtype of the contralateral tu-
mor was found. Multifocality in the lobe of the primary tumor
had the strongest association with contralateral carcinoma in
multivariate analysis with an OR of 2.62.
Table 1 Distribution of number of included patients per center
Country Hospital Number of
patients
The Netherlands UMC Utrecht 40
UMC Groningen 50
Leiden UMC 50
Radboud UMC 31
Maastricht UMC+ 15
Erasmus UMC 49
VU Medical Center 26
Amsterdam Medical Center 26
Antonie van Leeuwenhoek Hospital 23
USA University of California San Francisco 106
Weill Cornell Medical College 106
University of Chicago 128
Brigham and Women’s Hospital 145
The University of Arizona Medical
Center
77
Canada McGill University Health Center 99
France Centre Hospitalier Universitaire
de Nancy
137
Australia Royal North Shore Hospital 205
368 Langenbecks Arch Surg (2016) 401:365–373
Table 2 Descriptive statistics for the study population
Determinants Number Contralateral
carcinoma +
OR (95 % CI)
univariate analyses
p value OR (95 % CI)
multivariate analyses
p value
N 1313 426 (32 %)
Sex
Female 967 (74 %) 320 (75 %) 0.89 (0.69–1.14) 0.40
Male 346 (26 %) 106 (25 %)
Age 1.01 (1.00–1.02) 0.07 1.02 (1.01–1.04) 0.01
≤45 579 (44 %) 182 (43 %)
≥45 734 (56 %) 244 (57 %)
Size primary tumor US (mm) 1.00 (1.00–1.01) 0.41
<11 32 (3 %) 13 (4 %)
11–20 384 (37 %) 132 (39 %)
21–30 325 (31 %) 87 (25 %)
31–40 148 (14 %) 49 (14 %)
>40 162 (15 %) 61 (18 %)
Missing 262
FNA (Bethesda)
1 57 (5 %) 15 (4 %)
2 91 (8 %) 34 (9 %) 0.61 (0.33) 0.11 0.58 (0.21) 0.30
3 85 (8 %) 25 (7 %) 1.01 (0.64) 0.96 0.83 (0.35) 0.68
4 213 (19 %) 55 (15 %) 0.71 (0.43) 0.18 0.89 (0.37) 0.79
5 205 (19 %) 63 (18 %) 0.59 (0.41) 0.00 0.68 (0.37) 0.22
6 456 (41 %) 169 (47 %) 0.75 (0.53) 0.12 0.93 (0.50) 0.81
Missing 206
Nodal status
N0 979 (78 %) 397 (73 %) 1.56 (1.18–2.07) 0.00 1.89 (1.07–3.34) 0.03
N1a 269 (22 %) 109 (27 %)
Missing 65
Size primary tumor PA (mm) 1.01 (1.00–1.02) 0.07 1.02 (1.00–1.05) 0.03
11–20 618 (47 %) 197 (46 %)
21–30 370 (28 %) 115 (27 %)
31–40 163 (12 %) 49 (12 %)
>40 162 (12 %) 65 (15 %)
Angio-invasion
No 901 (78 %) 298 (79 %) 0.93 (0.69–1.26) 0.66
Yes 247 (22 %) 78 (21 %)
Missing 165
Capsular invasion
No 594 (59 %) 187 (60 %) 0.93 (0.71–1.22) 0.59
Yes 415 (41 %) 124 (40 %)
Missing 304
Extra-thyroidal growth
No 1006 (81 %) 307 (77 %) 94 (23 %) 1.56 (1.16–2.10) 0.00 1.02 (0.53–1.93) 0.96
Yes 231 (19 %)
Missing 76
Negative margins
No 374 (29 %) 121 (30 %) 0.99 (0.77–1.28) 0.95
Yes 898 (71 %) 289 (70 %)
Missing 41
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The rate of contralateral carcinomas is in agreement with
current literature that reports rates between 17 and 43%.Most
of these studies focused on contralateral carcinomas in prima-
ry papillary thyroid microcarcinomas (microPTC) [16, 17,
19–21], or had limited patient numbers, failed to report clear
in- and exclusion criteria, or excluded patients with FTC [25,
27–29]. In contrast, our study investigated contralateral carci-
noma in a large, well-described, and clinically relevant cohort,
in which primary tumors were macroDTC. In our study, the
rate of contralateral carcinomas was higher in PTC and
FvPTC compared to FTC and HTC, 34 versus 17 %. This is
in line with a study byMachens et al., who found significantly
more tumor multifocality in patients with PTC versus FTC
[30].
In our study, 82 % of all contralateral carcinomas were
microPTC. Based on several other studies, the clinical rele-
vance of microPTCs can be questioned. In an observational
trial performed in Japan, including 1235 patients with primary
microPTC, tumor progression of more than 3 mmwas noticed
in only 8.0 % of patients, novel nodal metastasis developed in
3.8 %, and only 6.8 % developed into clinical disease after
10 years of follow-up. Eventually, only 15 % of patients
underwent surgery [11, 31]. These low progression rates show
that these primary microPTCs rarely develop into clinically
significant thyroid carcinomas. Our study described contralat-
eral microcarcinomas, while this study addressed primary
microPTC, and currently, it is unknown whether the natural
course of the primary microPTC differs from those of contra-
lateral microPTC. However, this is indirectly investigated by
analyzing recurrence rates in the contralateral lobe in studies
where DTC is treated by lobectomy. In a study with up to
20 years of follow-up comparing patients with microPTC
treated with lobectomy versus treatment with total thyroidec-
tomy, no difference in overall survival or in recurrence rates
Table 2 (continued)
Determinants Number Contralateral
carcinoma +
OR (95 % CI)
univariate analyses
p value OR (95 % CI)
multivariate analyses
p value
Multifocality
No 1033 (79 %) 285 (67 %) 2.64 (2.01–3.47) 0.00 2.62 (1.60–4.29) 0.00
Yes 277 (21 %) 139 (33 %)
Missing 3
Subtype carcinoma
PTC 794 (61 %) 280 (67 %)
FvPTC 354 (27 %) 113 (27 %) 0.86 (0.66) 0.27 0.58 (0.35) 0.04
FTC 116 (9 %) 20 (5 %) 0.38 (0.23) 0.00 0.54 (0.22) 0.18
HTC 38 (3 %) 6 (1 %) 0.34 (0.14) 0.02 0.16 (0.03) 0.02
Missing 11
Size contralateral lobe (mm) 1.00 (1.00–1.00) 0.59
<10 261 (24 %) 68 (20 %)
>10–<15 254 (24 %) 85 (25 %)
>15–<25 262 (24 %) 81 (23 %)
>25 299 (28 %) 113 (33 %)
Missing 237
Number (N) of patients with a contralateral carcinoma is shown for each determinant. Odds–Ratios (OR) and p values are shown for the uni- and
multivariate analyses
US ultrasonography, FNA fine-needle aspiration, PA pathology
Table 3 Histological subtype of
the primary tumors versus the
histological subtype of the
contralateral tumor. Missing:
n= 14 (3 %)
Subtype of primary tumor
Subtype of
contralateral
tumor
PTC FvPTC FTC HTC Total
PTC 244 (88 %) 25 (23 %) 13 (65 %) 2 (33 %) 284 (69 %)
FvPTC 30 (11 %) 84 (76 %) 6 (30 %) 3 (50 %) 123 (30 %)
FTC 1 (0 %) 2 (2 %) 1 (5 %) 0 (0 %) 4 (1 %)
HTC 2 (1 %) 0 (0 %) 0 (0 %) 1 (17 %) 3 (1 %)
Total 277 (100 %) 111 (100 %) 20 (100 %) 6 (100 %) 414 (100 %)
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were found [5]. One might assume that in the remaining thy-
roid lobe, similar rates of contralateral carcinomas were pres-
ent as in our population. Furthermore, from autopsy reports, it
is known that when thyroid glands are thoroughly examined,
malignancy rates of up to 36 % are found which is similar to
our contralateral carcinoma rate [1, 32]. Altogether, the clini-
cal relevance of 82 % of the contralateral carcinomas found in
our study is questionable.
Currently, there is no consensus whether multifocal carci-
nomas arise as a result of true multicentricity or intrathyroidal
spread of a primary tumor, as it is underlined by the report of
the European Society of Endocrine Surgeons 2013 [33]. In our
study, no correlation was found between the histological sub-
type of the primary tumor and that of the contralateral carci-
noma. Moreover, even when the primary tumor was of follic-
ular or Hürthle cell origin, 99 % of the contralateral carcino-
mas was PTC. This suggests that true multicentricity is more
likely than intrathyroidal spread.
Patients with DTC have an excellent 10-year overall sur-
vival, but they do suffer from a relatively low quality of life
(QoL) in comparison with other cancers, such as breast or
colorectal cancer [34, 35]. This decreased QoL is expressed
in several adverse physical, psychological, social, and spiritu-
al challenges [34]. After RAI, patients had significantly more
complaints of hypo- or hyperthyroidism, resulting in a de-
creased QoL[35]. Therefore, one of the factors to improve
QoL of macroDTC patients is to pursue normal thyroid hor-
mone homeostasis by performing parenchyma-sparing opera-
tions. After thyroid lobectomy, hormone replacement might
be necessary in 10 to 50% of patients; this is highly correlated
to the TSH level and presence of microsomal antibodies. In
patients with low TSH level (<2.5 mIU/L) and without micro-
somal antibodies, the risk to become hormone replacement
dependent is only 7 %. Furthermore, after lobectomy, patients
needed a lower dose of levothyroxine and less adjustment
steps to become euthyroid [36–38]. Therefore, QoL might
improve by performing a lobectomy instead of total
thyroidectomy.
As the discussion continues, we believe treatment of DTC
will becomemore and more a patient-tailored matter, in which
the pros and cons of lobectomy or total thyroidectomymust be
weighed one by one, based on existing evidence and discussed
with the patient. The three main arguments in favor of total
thyroidectomy are the ability to perform RAI, the use of thy-
roglobulin as a follow-up marker, and the high rate of contra-
lateral carcinomas. Arguments in favor of lobectomy are re-
duced complication risk, especially recurrent laryngeal nerve
injury and persisting hypocalcaemia, reduced risk of hypothy-
roidism, and no risk of complications from RAI. Taken the
abovementioned arguments into account, we question wheth-
er, in case the ultrasound of the contralateral lobe does not
show suspicious lesions, the possible presence of microPTC
should be an argument in favor of total thyroidectomy.
Conclusion
This international multicenter study is the largest study per-
formed on patients with macroDTC and confirms that, in pa-
tients with macroDTC, the rate of contralateral carcinomas is
32 %. This study shows that these contralateral carcinomas
predominantly consist of microPTC.
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